Guggenheim initiated coverage of AbbVie with a Buy rating and $172 price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ABBV:
- AbbVie receives CHMP opinion recommending approval for upadacitinib
- AbbVie, Capsida announce expanded genetic medicines for eye diseases pact
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- AbCellera price target lowered to $32 from $40 at BMO Capital
- AbbVie downgraded to Peer Perform on valuation at Wolfe Research